For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $50.52 in the prior trading day, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $49.44, down -2.14%. In other words, the price has decreased by -$2.14 from its previous closing price. On the day, 1.0 million shares were traded.
Ratios:
Our goal is to gain a better understanding of AKRO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.25 and its Current Ratio is at 17.25. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 10 ’25 when Cheng Andrew sold 30,000 shares for $52.73 per share. The transaction valued at 1,581,994 led to the insider holds 686,062 shares of the business.
Graham G. Walmsley bought 200,000 shares of AKRO for $9,600,000 on Jan 30 ’25. The Director now owns 1,000,000 shares after completing the transaction at $48.00 per share. On Feb 05 ’25, another insider, Rolph Timothy, who serves as the Chief Scientific Officer of the company, sold 18,750 shares for $56.51 each. As a result, the insider received 1,059,630 and left with 170,237 shares of the company.
Stock Price History:
Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $17.86. The 50-Day Moving Average of the stock is 38.74%, while the 200-Day Moving Average is calculated to be 73.42%.
Shares Statistics:
A total of 69.61M shares are outstanding, with a floating share count of 65.02M. Insiders hold about 13.46% of the company’s shares, while institutions hold 92.34% stake in the company.
Earnings Estimates
The dynamic stock of Akero Therapeutics Inc (AKRO) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.93 and low estimates of -$1.25.
Analysts are recommending an EPS of between -$3.84 and -$4.27 for the fiscal current year, implying an average EPS of -$3.95. EPS for the following year is -$4.84, with 8.0 analysts recommending between -$4.29 and -$6.24.
